In Havana and Villa Clara, the Center for Molecular Immunology develops the phase 1 clinical trial of 2C12, in which patients from various oncological pathologies participate.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
In Havana and Villa Clara, the Center for Molecular Immunology develops the phase 1 clinical trial of 2C12, in which patients from various oncological pathologies participate.